PT - JOURNAL ARTICLE AU - Ng’ambi, Wingston AU - Babaye, Yusuf AU - Nyasulu, Paul AU - Jahn, Andreas AU - Kalua, Thoko AU - Longwe-Ngwira, Abiba AU - Odo, Michael AU - Namakhoma, Ireen AU - Nyirenda, Rose AU - O’Malley, Gabrielle TI - A capacity assessment of healthcare workers to provide second-line antiretroviral therapy in Malawi: 2016 AID - 10.1101/2021.10.20.21265306 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.20.21265306 4099 - http://medrxiv.org/content/early/2021/10/26/2021.10.20.21265306.short 4100 - http://medrxiv.org/content/early/2021/10/26/2021.10.20.21265306.full AB - INTRODUCTION According to the estimates by the World Health Organisation, Malawi is lagging behind for the number of patients that should have been on second-line ART. In settings like Malawi the low switching may be attributable to low knowledge of clinical assessment for first-line antiretroviral treatment (ART) failure. We analyzed the knowledge level of different cadres of health workers on the management of second-line ART.METHODS This cross-sectional study assessed whether the first-line ART providers were capable to provide second-line ART in Malawi. Descriptive statistics were conducted using STATA v15.0. The passing score was 80%. Associations were assessed using Chi-Square tests with a statistical significance set at P<0.05.RESULTS Of the 754 ART providers assessed, 290 (38%) were eligible to prescribe second-line ARVs. We observed significant differences for eligibility by cadre and district (P<0.001). Furthermore, 69% of the ART providers correctly identified second-line ARVs while 9% of the providers correctly chose second-line ARVs for management of different side-effects. Both competencies varied by cadre and district (P<0.001). Of the ART providers, 9% correctly interpreted the VL results which we found to significantly vary by cadre (P<0.001) and not districts. However, 78% of ART providers were able to prescribe correct dose of second-line ART which did not significantly vary by cadre (P=0.27). Spatial analysis showed Thyolo and Chiradzulu as high performing districts.CONCLUSIONS This assessment found that registered nurses had comparable knowledge to medical doctors with at least Bachelor of Medicine and Bachelor of Surgery and clinical officers with a Diploma in Clinical Medicine in most areas but not in correctly selecting second line ARVs. To strengthen task shifting approaches, capacity building should focus on how to correctly select second line regimen and interpret viral load results. Training activities should also consider regional and district-level variability in capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project was provided to I-TECH-Malawi by the United States Centers for Disease Control and Prevention (CDC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this assessment was obtained from the National Health Science Research Committee (Lilongwe, Malawi), University of Washington (Seattle, WA), and the Centers for Disease Control and Prevention, Center for Global Health Associate Director for Science (Atlanta, GA).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData should be accessed from the Corresponding AuthorARTAntiretroviral TherapyARVAntiretroviral DrugsCDCUnited States Centers for Disease Control and PreventionCSProCensus and Survey Processing System;DHADepartment of HIV/AIDSI-TECHInternational Training and Education Center for HealthHCWsHealth Care WorkersHIVHuman Immunodeficiency VirusMoHMinistry of HealthPEPFARU.S. President’s Emergency Plan for AIDS ReliefUNAIDSUnited Nations Programme on HIV/AIDSVLViral LoadWHOWorld Health Organisation